U.S. Therapeutic Plasma Exchange Market worth 260 M USD by 2021

Friday 22 July 2016, Amsterdam

The report, now available on ASDReports, "U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021", The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 Million by 2021, growing at a CAGR of 11% to 12% during the forecast period.

The growing prevalence of neurological diseases; increasing adoption of TPE procedures in rare disorders such as Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Neuromylitis Optica, Thrombotic Thrombocytopenic Purpura (TTP), and Cryoglobulinaemia; and growing awareness about the increasing clinical response rate of TPE procedures in various diseases in the U.S. are driving the growth in this market segment. However, factors such as high cost of therapeutic plasma exchange procedures, lack of awareness about the TPE process, lack of skilled professionals, and risks associated with therapeutic plasma exchange procedure are restraining the growth of the U.S. therapeutic plasma exchange market to a certain extent.

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

This study also provides information on the number of patients treated and the total number of TPE procedures performed for various diseases. Some of the major players in the U.S. therapeutic plasma exchange market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).